Uber Stock Barely Higher After Billion-Dollar Loss

Genocea Biosciences has been subject to an enormous amount of analyst love

Managing Editor
May 31, 2019 at 2:53 PM
facebook X logo linkedin


U.S. markets are taking a massive blow this afternoon, as President Donald Trump continues to ramp up global trade tensions. A pair of stocks also in focus today are ride-hailing service Uber Technologies Inc (NYSE:UBER) and drug name Genocea Biosciences Inc (NASDAQ:GNCA). Below, we will dive into what is moving the shares of UBER and GNCA.

UBER Shares Muted After Earnings Surprise

Shares of UBER are flat in afternoon trading, though the stock was seeing notable gains as recently as this morning. Last seen around $39.78, the Lyft rival is keeping its head above water after yesterday evening sharing a narrower-than-expected $1 billion first-quarter loss, and a 20% rise in quarterly revenue. Looking more broadly, the security is just below its May 10 opening share price of $42.

This morning, D.A. Davidson slashed its price target to $46 from $53, to what still would be record-high territory for the stock. Overall, five analysts are following the equity, three of which sport a tepid "hold" rating. However, the remaining two carry a "strong buy," while the stock's average 12-month price target stands at $53.83, a 35% upside to current levels.

Genocea Biosciences Nears Annual-High Territory

Drug stock GNCA has gapped 30.2% higher to trade at $5.86 at midday, earlier touching an intraday peak of $8.00 -- a chip shot from annual-high territory. The equity is soaring on the back of news that the company's vaccine candidate GEN-009 was selected to be featured in the American Society of Clinical Oncology's (ASCO) top 10 abstracts in immuno-oncology. GNCA has more than doubled year-to-date, and today is set to close back atop its 80-day moving average for the first time since its May 17 pullback.

Analysts have been extremely optimistic toward the biopharma. Coming into today, all three carried "buy" or "strong buy" recommendations, not to mention the stock's astronomical average 12-month price target of $25.67, which comes in at four-fold its current trading price.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI